Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.

doi:10.1200/JCO.21.01601

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2022

Dummer Reinhard, Long Georgina V, Robert Caroline, Tawbi Hussein A, Flaherty Keith T, Ascierto Paolo A, Nathan Paul D, Rutkowski Piotr, Leonov Oleg, Dutriaux Caroline, Mandalà Mario, Lorigan Paul, Ferrucci Pier Francesco, Grob Jean Jacques, Meyer Nicolas, Gogas Helen, Stroyakovskiy Daniil, Arance Ana, Brase Jan C, Green Steven, Haas Tomas, Masood Aisha, Gasal Eduard, Ribas Antoni, Schadendorf Dirk

Abstract excerpt

PURPOSE: Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600-mutant metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Imidazoles

Share to Neoplasms, Second Primary

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35030011
DOI: 10.1200/JCO.21.01601
PMCID: PMC9061149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.PMID 35030011Read ↗

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Semantic proximity Read ↗

Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.Semantic proximity Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.Semantic proximity Read ↗

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.